Clinical Trials (PDQ®)
|Phase III||Treatment||Completed||18 and over||NCI, Other||RTOG-9402|
CDR0000063603, CAN-NCIC-CE2, E-R9402, NCCTG-927252, SWOG-9402, INT-0149, CE2, NCT00002569
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
Further Study Information
- Compare the overall survival and time to tumor progression in patients with unifocal or multifocal, supratentorial, pure or mixed anaplastic oligodendroglioma treated with radiotherapy with or without procarbazine, lomustine, and vincristine (PCV).
- Compare the toxic effects of these 2 regimens in these patients.
- Compare the quality of life and neurologic function of patients treated with these 2 regimens.
OUTLINE: This is a randomized study. Patients are stratified by age (under 50 vs 50 and over), Karnofsky performance status (60-70% vs 80-100%), and tumor grade (moderately vs highly anaplastic). Within 8 weeks after diagnostic surgery, patients are randomized to 1 of 2 treatment arms.
- Arm I: Within 2 weeks after randomization, patients receive oral lomustine on day 1, oral procarbazine on days 8-21, and vincristine IV on days 8 and 29 (PCV). Treatment continues every 6 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning within 6 weeks after day 29 of course 4, patients undergo radiotherapy 5 days a week for 5.6 weeks followed by boost radiotherapy 5 days a week for 1 week.
- Arm II: Within 2 weeks after randomization, patients undergo radiotherapy as in arm I.
Quality of life is assessed at baseline; at time of CT or MRI scans during study; and every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of study therapy.
Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 292 patients (146 per arm) will be accrued for this study within 5.4 years.
- Histologically proven unifocal or multifocal, supratentorial, pure or mixed anaplastic oligodendroglioma
- Prior suspected or proven low-grade glioma allowed if current histologic proof of pure or mixed anaplastic oligodendroglioma
- Tumor must contain an unequivocal (at least 25%) oligodendroglial element and have 2 or more anaplastic features, 1 of which must be frequent mitoses or endothelial proliferation
- For mixed tumors, the non-oligodendroglial element must be astrocytic and the oligodendroglial or astroglial component may be anaplastic
- No evidence of spinal drop metastasis or spread to noncontiguous meninges
- MRI of spine not required for asymptomatic patients and patients not excluded based on pathologic evidence of local meningeal infiltration by underlying tumor
- No tumor that is predominantly located in the posterior fossa (i.e., brainstem or cerebellum)
- No spinal cord tumors
- 18 and over
- Karnofsky 60-100%
- Not specified
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 150,000/mm^3
- Bilirubin no greater than 2 times normal
- Serum glutamate oxaloacetate transaminase (SGOT) no greater than 2 times normal
- Alkaline phosphatase no greater than 2 times normal
- Creatinine no greater than 1.5 times normal
- No chronic lung disease unless diffusion capacity of lung for carbon monoxide (DLCO) is at least 60% predicted
- No active infection
- No other malignancy within the past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
- No prior chemotherapy
- No concurrent steroids as antiemetics
- Concurrent steroids allowed to control central nervous system (CNS) symptoms due to tumor-associated or radiotherapy-associated cerebral edema
- No prior radiotherapy to brain or head/neck
- Prior surgery allowed
Trial Lead Organizations/Sponsors
Radiation Therapy Oncology GroupNational Cancer Institute
North Central Cancer Treatment Group
Southwest Oncology Group
Eastern Cooperative Oncology Group
NCIC-Clinical Trials Group
|J. Gregory Cairncross||Study Chair|
|Steven R. Alberts||Study Chair|
|Karen L. Fink||Study Chair|
|Richard M. Hellman||Study Chair|
|Normand Laperriere||Study Chair|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00002569
ClinicalTrials.gov processed this data on October 20, 2014
Back to Top